ETS2 and prostate carcinoma: They found that Ets2-targeting TFO can act as a selective transcriptional repressor of Ets2 transcription in human prostate cancer cells, suggesting that the triplex formation was the functional mechanism of the anti-transcriptional activity of the Ets2-TFO (Carbone et al., 2003).